<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511732</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-TI-005</org_study_id>
    <nct_id>NCT00511732</nct_id>
  </id_info>
  <brief_title>18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Double-blind, Controlled, Stepwise Titration Study to Evaluate Dose Response to Prandial Administration of Inhaled Technosphere/Insulin or Technosphere in Patients With Type 2 Diabetes Mellitus Who Are Sub-optimally Treated</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mannkind Corporation</source>
  <brief_summary>
    <textblock>
      Designed to evaluate dose response of force-titrated prandial administration of TI as
      compared to placebo (TP) in subjects with Type 2 diabetes who were suboptimally controlled
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c change from baseline (week 6) to end of treatment (week 17)</measure>
    <time_frame>measured from week 6 (baseline) to week 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline.</measure>
    <time_frame>at weeks 4, 6, 11 and 17</time_frame>
    <description>Timepoints: 0 minutes (before meal) and at 15, 30, 60, 90, 120, 180, 240, and 300 minutes after TI administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline)</measure>
    <time_frame>at weeks 4, 6, 11 and 17</time_frame>
    <description>Timepoints: 0 minutes (before meal) and at 15, 30, 60, 90, 120, 180, 240, and 300 minutes after Technosphere Placebo administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose concentration compared to week 6 (baseline)</measure>
    <time_frame>at weeks 4, 6, 11 and 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Technosphere Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Technosphere Inhalation Powder</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere Insulin</intervention_name>
    <description>Technosphere Insulin Inhalation Powder</description>
    <arm_group_label>Technosphere Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere Placebo</intervention_name>
    <description>Technosphere Inhalation Powder</description>
    <arm_group_label>Technosphere Inhalation Powder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and females patients from 18 to &lt;80 years of age

          -  Clinical diagnosis of type 2 diabetes mellitus

          -  Duration of diabetes of &gt;3 years and &lt;20 years

          -  Glycemic control at upper end of acceptable level or sub-optimal in control (HbA1c
             between 7.0% and 12?0%)

          -  Confirmation of diagnosis of diabetes such as a history of 2 hour postprandial blood
             glucose &gt;11.1 mmol/L (200 mg/dL) or following a glucose tolerance test

          -  A minimum of 2 months of treatment with a stable dose of one or more of the following
             anti-hyperglycemic agents: sulphonylureas, alpha glucosidase inhibitors, metformin,
             meglitinides, thiazolidinediones and/or Lantus basal insulin therapy

          -  FBG:&gt;6 mmol/L (108 mg/dL)

          -  C-peptide: &gt;0.5 nmol/L

          -  BMI &lt;38 kg/m2

          -  Baseline DLco, FVC, FEV1 &gt;75% of predicted normal

          -  Subjects who, in the opinion of the Investigator, will be able to complete this study

          -  Written informed consent

        Exclusion Criteria:

          -  Severe complications of diabetes including history of: blindness from or grade III or
             IV diabetic retinopathy, renal failure requiring dialysis or transplantation,
             amputation of limbs or digits related to diabetic vasculopathy or foot ulcers

          -  Treatment with another investigational drug within 3 months prior to study entry and
             for the duration of the study

          -  History of drug or alcohol dependency

          -  Significant hepatic disease (as evidenced by ALT or AST &gt;3 times the normal upper
             reference range or bilirubin &gt;1.5 times the normal upper reference range)

          -  Significant renal disease (as evidenced by creatinine &gt;1.5 mg/dL for males or &gt;1.3
             mg/dL for females) or proteinuria &gt;1,000 mg/24 hours

          -  History of chronic obstructive pulmonary disease, or history of other known chronic
             pulmonary diseases, such as reactive airway disease, chronic bronchitis, emphysema, or
             asthma

          -  Heart disease graded as class III or class IV according to New York Heart Association
             criteria

          -  Prior treatment with , or participation in a clinical study involving an inhaled
             insulin product

          -  Smokers

          -  Current use of preprandial or prandially administered fast-acting or rapid acting
             insulin or insulin analogs

          -  Previous participation in a TI or TP clinical trial

          -  Allergy to insulin or to any drugs to be used as part of the clinical trial

          -  History of malignancy within 5 years of study entry (other than basal cell carcinoma)

          -  Anemia (hemoglobin level less than 11 g/dL for females or 12 g/dL for males at study
             entry)

          -  Diagnosis of Acquired Immunodeficiency Syndrome (AIDS) and Aids Related Complex A
             major psychiatric disorder that will preclude satisfactory participation in this study

          -  Subjects who have had a myocardial infarction or stroke within the preceding 6 months

          -  Prior diagnosis of systemic autoimmune or collagen vascular disease requiring previous
             or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine

          -  History of severe or multiple allergies

          -  Progressive fatal disease

          -  Recent loss (within the past 2 months) of &gt;5% of body weight

          -  Evidence of &quot;moderate&quot; or greater ketones in urine or history of ketoacidosis

          -  Use of medications known to modify glucose metabolism or the ability to recover from
             hypoglycemia such as oral, parenteral and inhaled steroids, or greater than 25 mg
             hydrochlorothiazide daily

          -  Women who are pregnant or lactating

          -  Women of childbearing potential practicing inadequate birth control (adequate birth
             control is defined as using oral contraceptives, condoms or diaphragms with
             spermicide, intrauterine devices, or surgical sterilization).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Boss</last_name>
    <role>Study Director</role>
    <affiliation>Mannkind Corporation</affiliation>
  </overall_official>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <last_update_submitted>April 27, 2012</last_update_submitted>
  <last_update_submitted_qc>April 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

